SCYNEXIS (NASDAQ: SCYX)
$1.40
(-1.1%)
-$0.02
Price as of April 18, 2024, 4:00 p.m. ET
SCYNEXIS Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
SCYNEXIS Company Info
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.